tm
Seeing Is Believing
tm
Seeing Is Believing
TRDA is currently covered by 2 analysts with an average price target of $20. This is a potential upside of $15.59 (353.51%) from yesterday's end of day stock price of $4.41.
Entrada Therapeutics's activity chart (see below) currently has 32 price targets and 32 ratings on display. The stock rating distribution of TRDA is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 23.17% with an average time for these price targets to be met of 95.11 days.
Highest price target for TRDA is $23, Lowest price target is $17, average price target is $20.
Most recent stock forecast was given by DEBJIT CHATTOPADHYAY from GUGGENHEIM on 08-Jun-2026. First documented stock forecast 23-Nov-2021.
Currently out of the existing stock ratings of TRDA, 4 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Feb-2026
$17
$12.59 (285.49%)
$20
4 months 18 days ago
(08-Jun-2026)
0/2 (0%)
$10.74 (171.57%)
Buy Since 03-Apr-2023
$20
5 months 18 days ago
(08-May-2026)
5/15 (33.33%)
$8.96 (81.16%)
175
Buy Since 26-Aug-2024
$23
$15.26 (197.16%)
$30
6 months 20 days ago
(06-Apr-2026)
0/4 (0%)
$9.12 (65.71%)
Buy Since 03-Apr-2023
$17
$9.26 (119.64%)
$20
1 years 2 months 19 days ago
(07-Aug-2025)
3/10 (30%)
$11.7 (220.75%)
177
Buy Since 04-Jan-2024
$30
$25.59 (580.27%)
$22
1 years 7 months 2 days ago
(24-Mar-2025)
0/2 (0%)
$19.2 (177.78%)
What is TRDA (Entrada Therapeutics) average time for price targets to be met?
Which analyst most recently updated their price target on TRDA (Entrada Therapeutics)?
Which analyst has the current lower performing score on TRDA (Entrada Therapeutics) with a proven track record?
Which analyst has the most public recommendations on TRDA (Entrada Therapeutics)?
Which analyst is the currently most bullish on TRDA (Entrada Therapeutics)?
Which analyst is the currently most reserved on TRDA (Entrada Therapeutics)?
